This finding could also be relevant for the future investigation of drug targets to treat these conditions, such as the current pharmaceutical use of the PPARγ agonist [thiazolidinedione (TZD)] to treat insulin resistance in patients with T2D, which is associated with numerous adverse side effects such as body weight gain, fluid retention, heart failure, bone fractures, and increased risk of bladder cancer (70). Here, PPARG is linked to Insulin resistance.